FDA clears Tixel for skin resurfacing

29 Mar 2021

Skin device Tixel, manufactured by Novoxel, has received clearance from the Food and Drug Administration (FDA) for dermatological procedures requiring ablation and resurfacing of the skin.

Mr Evgeny Piven, CEO of Novoxel said, “To get the first FDA clearance for Tixel was one of our primary goals. This achievement is the result of hard work by Novoxel employees, assisted by our worldwide key opinion leaders. We‘re very grateful that we can now offer this product to physicians in the United States. Since launching Tixel in Europe and many other countries several years ago, we have seen a growing demand from physicians and patients for our unique products.”


Log-in to post a comment